Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $150
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $200 to $150.
Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $200 to $150.